Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008808 · ClinicalTrials.gov registry record · Phase 1
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
A Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT06008808: Recruiting Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease, sponsored by Washington University School of Medicine.
NCT06008808 is a Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 41 participants, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06008808, a Phase 1 study of Graft-Versus-Host Disease and Graft Vs Host Disease, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readily available haploidentical donors. One of the risks of a haploidentical HCT is graft vs. host disease (GVHD), but it is difficult to reduce the incidence of GVHD without compromising the graft vs. leukemia (GVL) effect. The hypothesis of this study is that JAK inhibition with and without CTLA-4 Ig with haploidentical HCT may mitigate GVHD and cytokine release syndrome while retaining the GVL effect and improving engraftment.
Conditions Studied
Interventions
- DRUG Abatacept
- DRUG Ruxolitinib
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-05-07 |
| Est. Completion | 2026-12-11 |
| Phase | Phase 1 |
What NCT06008808 shows while recruiting
NCT06008808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 82-participant average among 38 other Graft-Versus-Host Disease trials with a reported enrollment target (50% lower).
The record links to 2 conditions, with Graft-Versus-Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Abatacept is the first listed.
NCT06008808 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06008808 about?
NCT06008808 is a clinical study titled "Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation". Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readil...
What is the current status of trial NCT06008808?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-05-07. Estimated completion is 2026-12-11.
What conditions does trial NCT06008808 study?
This clinical trial studies the following conditions: Graft-Versus-Host Disease, Graft Vs Host Disease.
What interventions are being tested in trial NCT06008808?
The interventions under investigation include: Abatacept (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT06008808?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06008808 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-Versus-Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06008808's enrollment target sits among peer trials
41 18th of 38 higher than 21 of 38 other Graft-Versus-Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Graft-Versus-Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
RECRUITING · Phase 1
-
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RECRUITING · Phase 1
-
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Optimizing PTCy Dose and Timing
ACTIVE NOT RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
ACTIVE NOT RECRUITING · Phase 1
-
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI